iTeos Therapeutics develops novel cancer immunotherapies and maintains a pipeline that includes drugs designed to influence the tumor microenvironment. The company is described as a biotech focused on new tumor immune therapies. Its development pipeline specifically includes agents that act on the tumor microenvironment. The article reports that iTeos recently received a strategic investment. The investors named are Boxer Capital and RA Capital Management. The amount of the investment was not disclosed in the article. iTeos Therapeutics is a clinical-stage biotechnology company developing next-generation immunotherapies that target the adenosine pathway and regulatory T cells (Tregs). Its lead programs are EOS-850, an adenosine A2A receptor antagonist in a Phase 1/2 study as a single agent and in combination, and EOS-448, a fully human ADCC‑enabled anti‑TIGIT antibody that entered the clinic. The company plans to initiate dosing for the combination cohorts of the EOS-850 trial in the second quarter of 2020 and recently initiated the Phase 1 portion of the EOS-448 Phase 1/2 study. Proceeds from the financing will support advancement of these clinical programs and additional first‑in‑class preclinical programs targeting the adenosine pathway and Tregs. iTeos is led by President and CEO Michel Detheux and is headquartered in Cambridge, MA with a research center in Gosselies, Belgium. iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on next-generation cancer immunotherapies targeting adenosine and regulatory T cell pathways. Its lead program, EOS-850, is a best-in-class adenosine A2A receptor antagonist currently in a Phase 1b/2a study across four European sites with planned expansion to the United States. A second program, EOS-448, is a fully human ADCC-enabled anti-TIGIT antibody expected to enter Phase 1 in Belgium in early 2020. The company maintains headquarters in Cambridge, MA and a research center in Gosselies, Belgium. iTeos was founded by the Ludwig Institute for Cancer Research and the de Duve Institute. Financially, the company recently received non-dilutive support and has previously completed a $75 million (€64 million) Series B financing in 2018 led by MPM Capital. iTeos Therapeutics develops next-generation cancer immunotherapies with a pipeline focused on modulating the tumor microenvironment. The company plans to move EOS100850, an insurmountable and non‑brain penetrant adenosine A2A receptor antagonist, into the clinic in 2018 and toward clinical proof‑of‑concept, and EOS884448, an anti‑TIGIT antibody, into the clinic in 2019. Its pipeline also includes additional drug candidates targeting the tumor microenvironment. iTeos intends to use the proceeds from the financing to accelerate clinical development of its immuno‑oncology pipeline and to expand into new U.S. offices in Cambridge, Massachusetts. The company is led by CEO Michel Detheux, Ph.D., and was founded out of the Ludwig Institute for Cancer Research and the de Duve Institute in 2011. iTeos Therapeutics develops immuno-oncology drugs, focused on targeting the A2A adenosine receptor, immune checkpoints and non-immunogenic (“cold”) tumors. Its lead candidate is a proprietary A2A antagonist, and the company has a portfolio of additional immuno-oncology programs. iTeos has licensed its IDO1 program, which is in Phase 1 development, to Pfizer. The company uses a platform to identify rational combinations of immunotherapies and novel targets and emphasizes translational tumor immunology and early clinical-trial design. iTeos is based in Gosselies, Belgium and is a spin-off from Ludwig Cancer Research and the de Duve Institute (UCL). The company is supported in part by the Walloon Region and the FEDER. The recent funding will support clinical development activities and advance the launch of a clinical trial.

Total raised

$228M

Funding rounds

6

Latest round

Series B

Latest activity

Apr 2020